- Home
- AOMR vs KZIA Comparison
AOMR vs KZIA Comparison
Compare AOMR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | KZIA |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.5M | 186.7M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AOMR | KZIA |
|---|---|---|
| Price | $7.34 | $8.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $10.35 | ★ $28.33 |
| AVG Volume (30 Days) | 121.8K | ★ 248.3K |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | ★ 18.03% | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.96 | $4.86 |
| 52 Week High | $9.48 | $17.40 |
Technical Indicators
Market Signals| Indicator | AOMR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 39.10 |
| Support Level | $7.04 | $6.72 |
| Resistance Level | $9.24 | $8.18 |
| Average True Range (ATR) | 0.18 | 0.67 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 82.98 | 48.51 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in first and second lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rate and credit cycles. The company operates in a single operating segment, which is to acquire, invest in, and finance mortgage-related assets.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.